250
Views
0
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Cancer vaccines from melanoma to ovarian cancer: good immune responses obtained

Pages 725-727 | Published online: 10 Jan 2014

References

  • Vermorken JB, Claessen AM, van Tinteren H et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet353(9150), 345–350 (1999).
  • Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet363(9409), 594–599 (2004).
  • Van den Eynde BJ, Boon T. Tumor antigens recognized by T lymphocytes. Int. J. Clin. Lab. Res.27(2), 81–86 (1997).
  • Kawakami Y, Robbins PF, Rosenberg SA. Human melanoma antigens recognized by T lymphocytes. Keio. J. Med.45(2), 100–108 (1996).
  • Castelli C, Rivoltini L, Andreola G, Carrabba M, Renkvist N, Parmiani G. T-cell recognition of melanoma-associated antigens. J. Cell. Physiol.182(3), 323–331 (2000).
  • Ward S, Dalgleish A. Therapeutic cancer vaccines. Vaccine (2007) (Epub ahead of print).
  • Dalgleish A. Overcoming technical challenges in the development of cancer vaccines. IDrugs10(7), 463–467 (2007).
  • Sabbatini P, Odunsi K. Immunologic approaches to ovarian cancer treatment. J. Clin. Oncol.25(20), 2884–2893 (2007).
  • Odunsi K, Qian F, Matsuzaki J et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc. Natl Acad. Sci. USA104(31), 12837–12842 (2007).
  • Dalgleish AG, Whelan MA. Cancer vaccines as a therapeutic modality: the long trek. Cancer Immunol. Immunother.55(8), 1025–1032 (2006).
  • den Brok MH, Sutmuller RP, Nierkens S et al. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. Cancer Res.66(14), 7285–7292 (2006).
  • Bae SH, Park YJ, Park JB, Choi YS, Kim MS, Sin JI. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy. Clin. Cancer Res.13(1), 341–349 (2007).
  • Nishisaka N, Maini A, Kinoshita Y et al. Immunotherapy for lung metastases of murine renal cell carcinoma: synergy between radiation and cytokine-producing tumor vaccines. J. Immunother.22(4), 308–314 (1999).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.